Colorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality worldwide, representing a major public health challenge. Despite advances in screening strategies, surgical techniques, and systemic therapies, patient prognosis is often compromised by late diagnosis, tumor heterogeneity, and therapeutic resistance. In recent years, the integration of advanced imaging analytics and artificial intelligence (AI) has opened new avenues for precision oncology. Radiomics, defined as the high-throughput extraction of quantitative features from medical images, has emerged as a promising tool to capture intratumoral heterogeneity and predict clinical outcomes in a non-invasive manner. When combined with AI, particularly machine learning and deep learning approaches, radiomics enables the development of predictive and prognostic models that may support treatment personalization. This narrative review provides a comprehensive overview of CRC epidemiology and risk factors, summarizes current diagnostic and clinical management strategies, and focuses extensively on radiomics and AI applications in CRC, including workflow standardization, feature extraction, clinical applications, and challenges for implementation in daily practice.
The incidence of Type 1 Diabetes (T1D) in children and adolescents is increasing by 3–4
Neck fractures of the fifth metacarpal are frequent hand injuries. Surgical intervention is indicated for fractures with > 30° flexion angulation, rotational deformities, or shortening > 3 mm. Various techniques, including K-wire fixation, plating, and minimally invasive systems can be used. This study evaluates the efficacy of the Minimally Invasive Reduction and Osteosynthesis System (MIROS) for treating displaced fifth metacarpal neck fractures. A retrospective review of patients treated with MIROS between 2019 and 2024 was conducted. Patients aged 18–80 years with unstable neck fractures of the fifth metacarpal were included, excluding open, pathological, or polytrauma cases. Radiological outcomes were assessed through Palmar Tilt Angle (PTA) and Lateral Tilt Angle (LTA) measurements pre- and postoperatively. Secondary outcomes included surgery duration, radiation exposure, healing time, and complications. Fifty-two patients (44 men) were included, with a mean age of 35.1 ± 15.1 years. Postoperative improvements in PTA (from 35.4 ± 16.6 to 15.9° ± 9.3; p < 0.0001) and LTA (from 56.7 ± 14.7 to 29.3 ± 11.9; p < 0.0001) were significant. Mean surgery duration was 37.4 ± 18.1 min, and radiological healing time averaged 2.3 ± 1.4 months. The complication rate was 7.7
Background Concomitant medications may potentially affect the outcome of cancer patients. In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess the impact of concomitant use of proton pump inhibitors (PPI), statins, or metformin on outcome of patients with metastatic urothelial cancer (mUC) receiving second-line pembrolizumab. Methods We collected data from the hospital medical records of patients with mUC treated with pembrolizumab as second-line therapy at 87 institutions from 22 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate. We carried out a survival analysis by a Cox regression model. Results A total of 802 patients were eligible for this retrospective study; the median follow-up time was 15.3 months. PPI users compared to non-users showed inferior PFS (4.5 vs. 7.2 months, p = 0.002) and OS (8.7 vs. 14.1 months, p < 0.001). Concomitant PPI use remained a significant predictor of PFS and OS after multivariate Cox analysis. The use of statins or metformin was not associated with response or survival. Conclusions Our study results suggest a significant prognostic impact of concomitant PPI use in mUC patients receiving pembrolizumab in the real-world context. The mechanism of this interaction warrants further elucidation.
